Burstein HJ - Search Results

1

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Burstein HJ. Burstein HJ. N Engl J Med. 2020 Dec 24;383(26):2557-2570. doi: 10.1056/NEJMra1307118. N Engl J Med. 2020. PMID: 33369357 Review. No abstract available.

2

Ductal carcinoma in situ of the breast.

Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Burstein HJ, et al. N Engl J Med. 2004 Apr 1;350(14):1430-41. doi: 10.1056/NEJMra031301. N Engl J Med. 2004. PMID: 15070793 Review. No abstract available.

3

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. Winer EP, et al. Among authors: burstein hj. J Clin Oncol. 2005 Jan 20;23(3):619-29. doi: 10.1200/JCO.2005.09.121. Epub 2004 Nov 15. J Clin Oncol. 2005. PMID: 15545664 Review.

4

The distinctive nature of HER2-positive breast cancers.

Burstein HJ. Burstein HJ. N Engl J Med. 2005 Oct 20;353(16):1652-4. doi: 10.1056/NEJMp058197. N Engl J Med. 2005. PMID: 16236735 No abstract available.

5

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP. Harris LN, et al. Among authors: burstein hj. Clin Cancer Res. 2007 Feb 15;13(4):1198-207. doi: 10.1158/1078-0432.CCR-06-1304. Clin Cancer Res. 2007. PMID: 17317830 Clinical Trial.

6

Biological basis of breast cancer: an introduction.

Burstein HJ. Burstein HJ. Semin Oncol. 2007 Apr;34(2 Suppl 3):S1-3. doi: 10.1053/j.seminoncol.2007.03.018. Semin Oncol. 2007. PMID: 17512430 No abstract available.

7

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer.

Mayer EL, Carey LA, Burstein HJ. Mayer EL, et al. Among authors: burstein hj. Breast Cancer Res. 2007;9(5):110. doi: 10.1186/bcr1755. Breast Cancer Res. 2007. PMID: 17888189 Free PMC article.

8

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP. Lin NU, et al. Among authors: burstein hj. J Clin Oncol. 2008 Apr 20;26(12):1993-9. doi: 10.1200/JCO.2007.12.3588. J Clin Oncol. 2008. PMID: 18421051 Free PMC article. Clinical Trial.

9

Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer.

Burstein HJ, Souter I, D'Alessandro HA, Sgroi DC. Burstein HJ, et al. N Engl J Med. 2009 Aug 13;361(7):699-707. doi: 10.1056/NEJMcpc0902224. N Engl J Med. 2009. PMID: 19675333 No abstract available.

10

Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age.

Burstein HJ. Burstein HJ. Breast. 2009 Oct;18 Suppl 3:S135-6. doi: 10.1016/S0960-9776(09)70288-7. Breast. 2009. PMID: 19914532 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters